$MRVI

Millennium group lists 4.9% holding in Maravai (NASDAQ: MRVI) on 13G

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G reporting a shared voting and dispositive power over 7,228,864 shares of Maravai LifeSciences Holdings, Inc. Class A Common Stock, which represents a 4.9% stake. The filing indicates they had briefly exceeded 5% beneficial ownership on May 6, 2026, but were below that threshold by the filing date, with a Joint Filing Agreement dated May 11, 2026. This is a passive investment disclosure, as indicated by the use of Schedule 13G.

Original reporting
Published May 13, 2026, 5:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 13, 2026, 6:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$MRVI
Neutral
medium confidence
Mentioned
$MRVI
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$MRVINeutralLow
01

Why it matters

The disclosure is a passive investment with limited immediate market impact, but it signals institutional interest in Maravai.

02

Market read

The filing indicates institutional interest but is unlikely to cause significant short-term trading activity.

03

What to watch

The filing does not indicate any activist intent; however, changes in ownership structure or subsequent filings could alter the outlook.

Timing: short-term

Background

Millennium Management LLC filed a Schedule 13G reporting a 4.9% passive stake in Maravai LifeSciences, briefly exceeding the 5% threshold on May 6, 2026.

Company-level read

Ticker impact

$MRVINeutralMedium confidence
Context

The filing indicates a passive investment with a 4.9% stake, slightly below the 5% reporting threshold, suggesting limited immediate influence.

Expected impact

Minimal short-term price movement expected; potential for increased interest if stake exceeds 5% in the future.

Evidence & confidence

Passive investment filings typically do not cause significant market reactions unless they cross reporting thresholds or signal strategic shifts.

Market effects

Limited; the life sciences sector may see minor investor interest but no significant shifts.

Negligible; the filing pertains to a US-based company and investor.

Low; the news is specific to a passive investment disclosure.

Counterpoint

While the stake is below 5%, it could signal potential future activism or strategic interest, warranting closer monitoring.

Key entities

  • Millennium Management LLC

    A global investment management firm.

  • Maravai LifeSciences Holdings, Inc.

    A provider of life sciences tools and services.

Related articles

$TEMHighAI 8/10

TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial

Shares of BioNTech (BNTX), Moderna (MRVI), Regeneron (RGEN), and Novavax (NVAX) rose 20%, 25%, 6%, and 6% respectively after a Moderna-Merck cancer vaccine trial succeeded. Analysts expect benefits for Merck and suppliers like Repligen, Danaher, Thermo Fisher, and Maravai. TEM stock gained 2% YTD, with 8/16 analysts rating it 'Buy' or higher, and a 27% potential upside from its last close.

$MRVIMedAI 8/10

Maravai (MRVI) Q2 2026 Earnings Call Transcript

Maravai LifeSciences (MRVI) reported Q2 2026 revenue of $51.4 million, up 8.5% year over year, with TriLink at $34.7 million and Cygnus at $16.8 million. Adjusted EBITDA was $8.7 million, and GAAP net loss was $21.6 million. Full-year guidance: revenue $205-$215 million and adjusted EBITDA $33-$35 million.

$MRVIMed

MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI): Results of Operations and Financial Condition

MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Second quarter 2026 total revenue up 9% from prior year SAN DIEGO, Calif., — August 6, 2026 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents a

$MAIRMedAI 8/10

Billionaire Tycoon Ernesto Bertarelli Buys $219 Million in Madison Air Solutions Shares. What Does This Mean for Investors?

Billionaire Ernesto Bertarelli indirectly purchased 8.8 million shares of Madison Air Solutions (MAIR) at $24.97 per share, totaling $219 million. The acquisition was made through K.C. Armada, LP, bringing his indirect ownership to 11% of the company. MAIR's stock closed at $28.51, a 14% premium over the purchase price. The company has a market cap of $14.3 billion and expects 18% revenue growth this fiscal year.

$STXMed

Moody’s upgrades Seagate Data rating on AI demand strength

Moody's upgraded Seagate Data's corporate family rating to Ba1 from Ba2, citing AI-driven demand for high-capacity HDDs. The agency expects revenues to grow over 30% annually, reaching $20B, and debt to EBITDA to fall below 0.5x. Seagate faces risks from revenue concentration and pricing pressures. The company had $1.7B in cash and access to a $1.3B credit facility as of July 2026.